In October 2004, Magnum Therapeutics was acquired by Introgen Therapeutics Inc (Nasdaq: INGN), a Texas based firm that was itself already SBIR involved. Magnum's primary assets were the right to receive funding under a grant from the National Institutes of Health. Conduct of the work under that grant transferred to Introgen.
